Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Jonathan Barker; Giampiero Girolomoni; Alexander Egeberg; Joao Goncalves; Burkhard Pieper; Taegyun Kang

doi:10.1080/09546634.2019.1610553

Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Jonathan Barker^*, Giampiero Girolomoni, Alexander Egeberg, Joao Goncalves, Burkhard Pieper, Taegyun Kang

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

24 Citations (Scopus)

199 Downloads (Pure)

Abstract

Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings. Several biosimilar drugs based on the anti-TNF agents adalimumab, infliximab, and etanercept are now available for use in patients with psoriasis. The favorable cost differential of biosimilars is expected to improve access to biologic therapy for biologic-naive psoriasis patients, who are often undertreated. Also, substantial cost savings can be made if patients are switched to biosimilars. To date, most clinical testing of anti-TNF biosimilars approved for use in psoriasis has been performed in patients with rheumatoid arthritis, and the results extrapolated to psoriasis. Although this may initially raise concerns for clinicians looking to start their psoriasis patients on biologic treatment with a biosimilar or switch from an original biologic to a biosimilar, the process of extrapolation is tightly regulated and scientifically justified. Furthermore, available real-world evidence of the safety and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with rheumatoid arthritis. When equipped with the appropriate knowledge, clinicians should have confidence to use biosimilars for the treatment of psoriasis.

Original language	English
Journal	JOURNAL OF DERMATOLOGICAL TREATMENT
Early online date	16 May 2019
DOIs	https://doi.org/10.1080/09546634.2019.1610553
Publication status	E-pub ahead of print - 16 May 2019

Keywords

Biosimilars
psoriasis
tumor necrosis factor

Access to Document

10.1080/09546634.2019.1610553Licence: CC BY-NC-ND

Anti-TNF biosimilars in psoriasis_BARKER_Accepted17April2019_Epub16May2019_GOLD VoRFinal published version, 1.39 MBLicence: CC BY-NC-ND

Cite this

@article{92d0eaea3c4249b5b3fd40fb60b29f51,

title = "Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience",

abstract = "Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings. Several biosimilar drugs based on the anti-TNF agents adalimumab, infliximab, and etanercept are now available for use in patients with psoriasis. The favorable cost differential of biosimilars is expected to improve access to biologic therapy for biologic-naive psoriasis patients, who are often undertreated. Also, substantial cost savings can be made if patients are switched to biosimilars. To date, most clinical testing of anti-TNF biosimilars approved for use in psoriasis has been performed in patients with rheumatoid arthritis, and the results extrapolated to psoriasis. Although this may initially raise concerns for clinicians looking to start their psoriasis patients on biologic treatment with a biosimilar or switch from an original biologic to a biosimilar, the process of extrapolation is tightly regulated and scientifically justified. Furthermore, available real-world evidence of the safety and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with rheumatoid arthritis. When equipped with the appropriate knowledge, clinicians should have confidence to use biosimilars for the treatment of psoriasis.",

keywords = "Biosimilars, psoriasis, tumor necrosis factor",

author = "Jonathan Barker and Giampiero Girolomoni and Alexander Egeberg and Joao Goncalves and Burkhard Pieper and Taegyun Kang",

year = "2019",

month = may,

day = "16",

doi = "10.1080/09546634.2019.1610553",

language = "English",

journal = "JOURNAL OF DERMATOLOGICAL TREATMENT",

issn = "0954-6634",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Anti-TNF biosimilars in psoriasis

T2 - from scientific evidence to real-world experience

AU - Barker, Jonathan

AU - Girolomoni, Giampiero

AU - Egeberg, Alexander

AU - Goncalves, Joao

AU - Pieper, Burkhard

AU - Kang, Taegyun

PY - 2019/5/16

Y1 - 2019/5/16

N2 - Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings. Several biosimilar drugs based on the anti-TNF agents adalimumab, infliximab, and etanercept are now available for use in patients with psoriasis. The favorable cost differential of biosimilars is expected to improve access to biologic therapy for biologic-naive psoriasis patients, who are often undertreated. Also, substantial cost savings can be made if patients are switched to biosimilars. To date, most clinical testing of anti-TNF biosimilars approved for use in psoriasis has been performed in patients with rheumatoid arthritis, and the results extrapolated to psoriasis. Although this may initially raise concerns for clinicians looking to start their psoriasis patients on biologic treatment with a biosimilar or switch from an original biologic to a biosimilar, the process of extrapolation is tightly regulated and scientifically justified. Furthermore, available real-world evidence of the safety and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with rheumatoid arthritis. When equipped with the appropriate knowledge, clinicians should have confidence to use biosimilars for the treatment of psoriasis.

AB - Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings. Several biosimilar drugs based on the anti-TNF agents adalimumab, infliximab, and etanercept are now available for use in patients with psoriasis. The favorable cost differential of biosimilars is expected to improve access to biologic therapy for biologic-naive psoriasis patients, who are often undertreated. Also, substantial cost savings can be made if patients are switched to biosimilars. To date, most clinical testing of anti-TNF biosimilars approved for use in psoriasis has been performed in patients with rheumatoid arthritis, and the results extrapolated to psoriasis. Although this may initially raise concerns for clinicians looking to start their psoriasis patients on biologic treatment with a biosimilar or switch from an original biologic to a biosimilar, the process of extrapolation is tightly regulated and scientifically justified. Furthermore, available real-world evidence of the safety and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with rheumatoid arthritis. When equipped with the appropriate knowledge, clinicians should have confidence to use biosimilars for the treatment of psoriasis.

KW - Biosimilars

KW - psoriasis

KW - tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=85066018383&partnerID=8YFLogxK

U2 - 10.1080/09546634.2019.1610553

DO - 10.1080/09546634.2019.1610553

M3 - Review article

AN - SCOPUS:85066018383

SN - 0954-6634

JO - JOURNAL OF DERMATOLOGICAL TREATMENT

JF - JOURNAL OF DERMATOLOGICAL TREATMENT

ER -

Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this